Identification of phenotypic clusters of nonsteroidal anti-inflammatory drugs exacerbated respiratory disease

Lee, H. Y.; Ye, Y. M.; Kim, S. H.; Ban, Ga Young; Kim, S. C.; Kim, J. H.; Shin, Yoo Seob; Park, Hae‐Sim

doi:10.1111/all.13075

Cited by 39 publications

(36 citation statements)

References 42 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Newly described subphenotypes and emerging subendotypes of N-ERD are potentially relevant to the development of new treatments, such as biologics. Novel mechanisms that can be subendotypes are continually being identified (36,37).…”

Section: Complex Molecular Pathobiology Defines New Endotypes and Submentioning

confidence: 99%

Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases

Agache

Akdiş

2019

Journal of Clinical Investigation

216

184

View full text Add to dashboard Cite

in which microRNAs (miRNAs) play a central role (Table 3). High-throughput profiling studies of well-characterized patients, including analyses of gene expression (e.g., microarrays and RNA sequencing transcriptomics), can help to identify combined signatures for type 2 and non-type 2 endotypes. They are enriching the available data for the identification of new potential targets. As critical components in the regulation of tissue homeostasis, miRNAs represent a very attractive field of precision medicine research in asthma and allergic diseases, as they have been linked to many biological mechanisms underlying Th2 cell and macrophage polarization, regulation of ILC2 biology, steroidresistant asthma phenotype, airway smooth muscle dysfunction, and impaired antiviral innate immunity (Table 3 and refs. 15-25). Thus, miRNAs represent a modifiable downstream target that will expand the precision medicine approach beyond the type 2/ non-type 2 paradigm. In one notable example of this approach, the use of gene expression microarrays on bronchial epithelial cells obtained from patients with asthma led to the identification of periostin, an IL-13-responsive biomarker (26-30). However, expression signatures are not highly specific for type 2 asthma: a recent study showed type 2 airway gene expression in a subset of patients with chronic obstructive pulmonary disease (COPD) (31).

show abstract

Section: Complex Molecular Pathobiology Defines New Endotypes and Submentioning

confidence: 99%

Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases

Agache

Akdiş

2019

Journal of Clinical Investigation

216

184

View full text Add to dashboard Cite

show abstract

“…213 As the underlying mechanism is related to arachidonic acid metabolism, potential biomarkers focus on determining leukotriene and prostaglandin metabolites. Therefore, urinary LTE4 has been reported as a useful biomarker to distinguish between different sub-phenotypes in NERD, 214 between NERD and aspirintolerant asthma 214 and phenotypes with skin involvement (NIUA and NECD) . 215 Sensitivity and specificity of urinary LTE4 for identifying NERD has been reported to range from 0.55-0.81 and 0.77-0.82, respectively, which depends on the detection method used.…”

Section: Immunologically-mediated Non-specific Reactionsmentioning

confidence: 99%

Biomarkers in the Diagnosis and Therapy of Allergic Diseases and Asthma

Breiteneder¹,

Peng²,

Agache³

et al. 2020

Preprint

View full text Add to dashboard Cite

Modern healthcare requires a proactive and individualized response to diseases, combining precision diagnosis and personalized treatment. Accordingly, the approach to patients with allergic diseases encompasses novel developments in the area of personalized medicine, disease phenotyping and endotyping and the development and application of reliable biomarkers. A detailed clinical history and physical examination followed by the detection of IgE immunoreactivity against specific allergens still represents the state of the art. However, nowadays, further emphasis focuses on the optimization of diagnostic and therapeutic standards and a large number of studies have been investigating the biomarkers of allergic diseases, including asthma, atopic dermatitis, allergic rhinitis, food allergy, urticaria and anaphylaxis. Various biomarkers have been developed by omics technologies, some of which lead to a better classification of the distinct phenotypes or endotypes. The introduction of biologicals to clinical practice increases the need for biomarkers for patient selection, prediction of outcomes and monitoring, to allow for an adequate choice of the duration of these costly and long-lasting therapies. Escalating healthcare costs together with questions on the efficacy of the current management of allergic diseases requires further development of a biomarker-driven approach. Here, we review biomarkers in diagnosis and treatment of asthma, atopic dermatitis, allergic rhinitis, viral infections, chronic rhinosinusitis, food allergy, drug hypersensitivity and allergen-immunotherapy with a special emphasis on specific IgE, microbiome and epithelial barrier. In addition, EAACI guidelines on biologicals are discussed within the perspective of biomarkers.

show abstract

“…A cluster analysis of 302 Korean patients with respiratory symptoms found four distinct subtypes with different clinical/biochemical findings and asthma exacerbations. 49 Nonsteroidal anti-inflammatory drugs commonly induce urticaria/angioedema.…”

Section: Drug Allergymentioning

confidence: 99%

Highlights and recent developments in food and drug allergy, and anaphylaxis in EAACI Journals (2017)

Eigenmann

Akdiş²,

Bousquet

et al. 2018

Pediatric Allergy Immunology

View full text Add to dashboard Cite

This review highlights research advances and important achievements in food allergy, anaphylaxis, and drug allergy that were published in the Journals of the European Academy of Allergy and Clinical Immunology (EAACI) in 2017. Food allergy and anaphylaxis research have continued to rapidly accelerate, with increasing numbers of outstanding developments in 2017. We saw new studies on the mechanisms, diagnosis, prevention of food allergy, and novel food allergens. Drug hypersensitivity, as well as hereditary angioedema, has been highlighted in the present review as the focus of recent developments. The EAACI owns three journals: Allergy, Pediatric Allergy and Immunology (PAI), and Clinical and Translational Allergy (CTA). One of the major goals of the EAACI is to support health promotion in which prevention of allergy and asthma plays a critical role and to disseminate the knowledge of allergy to all stakeholders including the EAACI junior members. This paper summarizes the achievements of 2017 in anaphylaxis, and food and drug allergy. K E Y W O R D Sanaphylaxis, drug allergy, food allergy, hypersensitivity

show abstract

Identification of phenotypic clusters of nonsteroidal anti-inflammatory drugs exacerbated respiratory disease

Abstract: We found four distinct subtypes with different clinical/biochemical findings and asthma exacerbations in a NERD cohort. These findings suggest that stratified strategies by applying subtype classification may help achieve better outcomes in the management of NERD.

Cited by 39 publications

References 42 publications

Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases

Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases

Biomarkers in the Diagnosis and Therapy of Allergic Diseases and Asthma

Highlights and recent developments in food and drug allergy, and anaphylaxis in EAACI Journals (2017)

Contact Info

Product

Resources

About